Markets

Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session

Cardiome Pharma Corp.CRME was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.95 to $3.10 in the past one-month time frame.

None of the estimates for this stock were revised in the last 30 days and the Zacks Consensus Estimate also remained unchanged. Friday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Currently, Cardiome Pharma carries a Zacks Rank #4 (Sell).

Cardiome Pharma Corporation Price

Cardiome Pharma Corporation Price | Cardiome Pharma Corporation Quote

A better-ranked stock in the same industry is Infinity Pharmaceuticals, Inc. INFI , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is CRME going up? Or down? Predict to see what others think: Up or Down

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cardiome Pharma Corporation (CRME): Free Stock Analysis Report

Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

INFI

Other Topics

Investing Stocks

Latest Markets Videos